Literature DB >> 7613616

Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat.

P Fernyhough1, L T Diemel, J Hardy, W J Brewster, L Mohiuddin, D R Tomlinson.   

Abstract

Manipulation of neurotrophic support is a developing strategy for new therapy aimed at neurodegenerative diseases. This study demonstrates reduced content and retrograde transport of endogenous nerve growth factor (NGF) in sciatic nerve of diabetic rats. There were also reductions in the diabetic rats in NGF protein and mRNA in skin and muscle of the hindlimb. These deficits correlated with reductions in substance P and calcitonin gene-related peptide--both products of NGF-influenced genes in primary afferents. These manifestations of deficient neurotrophic support were corrected by intensive insulin treatment and surmounted by administration of exogenous human recombinant NGF in a dose-related manner. Impaired neurotrophic support may, therefore, participate in the pathogenesis of diabetic and other peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613616     DOI: 10.1111/j.1460-9568.1995.tb01098.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

Review 1.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

2.  Neuronal nitric oxide synthase mRNA upregulation in rat sensory neurons after spinal nerve ligation: lack of a role in allodynia development.

Authors:  Z D Luo; S R Chaplan; B P Scott; D Cizkova; N A Calcutt; T L Yaksh
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

Review 3.  Axon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia.

Authors:  Warren G Tourtellotte
Journal:  Am J Pathol       Date:  2015-12-24       Impact factor: 4.307

Review 4.  The role of axonal cytoskeleton in diabetic neuropathy.

Authors:  W G McLean
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

5.  Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy.

Authors:  R E Schmidt; D A Dorsey; L N Beaudet; S B Plurad; C A Parvin; M S Miller
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

6.  Cardiac innervation and sudden cardiac death.

Authors:  Masaki Ieda; Keiichi Fukuda
Journal:  Curr Cardiol Rev       Date:  2009-11

7.  Vascular endothelial growth factor gene transfer for diabetic polyneuropathy.

Authors:  John A Kessler
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 8.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

9.  Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes.

Authors:  Beatriz Duran-Jimenez; Darin Dobler; Sarah Moffatt; Naila Rabbani; Charles H Streuli; Paul J Thornalley; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

10.  Engineered zinc finger protein-mediated VEGF-a activation restores deficient VEGF-a in sensory neurons in experimental diabetes.

Authors:  Elizabeth J Pawson; Beatriz Duran-Jimenez; Richard Surosky; Heather E Brooke; S Kaye Spratt; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.